ASH Announces New ASH-AMFDP Hematology Scholars, First 10 Sites Join ASH Research Collaborative SCD Clinical Trials Network, and more

ASH Publishes Adapted Clinical Practice Guidelines for Management of VTE in Latin America

The American Society of Hematology (ASH), in partnership with 12 Latin American hematology societies representing 10 countries, has published adapted clinical practice guidelines for the management of venous thromboembolism (VTE) in Latin America.

Despite the prevalence of VTE in Latin America, treatment of patients in the region can be a challenge. Individuals of lower socioeconomic status often lack access to health care services, medication, and education. Also, some technologies are not available or feasible for use in some medical centers in Latin American countries.

Recognizing these considerations, ASH convened a guidelines panel including experts from hematology societies in Latin America to identify and address the clinical questions and needs of patients and providers in the region. Using systematic evidence reviews done for the ASH VTE guidelines on the Treatment of Deep Vein Thrombosis and Pulmonary Embolism and the Optimal Management of Anticoagulation Therapy, the panel adapted evidence-based guidelines with special considerations such as feasibility, affordability, and equity issues to more effectively treat VTE patients throughout Latin America.

The 17 recommendations were published in Blood Advances August 10, and are available in English, Spanish, and Portuguese. Clinical tools and educational resources are also available to help patients, hematologists, and other health care providers understand and implement the recommendations.

“In collaboration with our partners in the region, ASH adapted these guidelines so Latin American patients and clinicians alike can have the evidence-based tools they need to make informed decisions about managing VTE within the unique health care setting of their country,” said ASH President Martin S. Tallman, MD.

These guidelines are the most recent product of ASH’s larger guideline development initiative. A second adapted guideline on the prevention of VTE is expected in late 2021.

Find the adapted guidelines and learn more about the initiative at hematology.org/VTEguidelines.


Congratulations to the New ASH-AMFDP Hematology Scholars!

ASH is pleased to announce the recipients of the American Society of Hematology-Harold Amos Medical Faculty Development Program (ASH-AMFDP) Award, a partnership between ASH and the Robert Wood Johnson Foundation: Lachelle Dawn Weeks, MD, PhD, of Dana-Farber Cancer Institute, and Emilio Ramos, MD, PhD, of University of California, San Francisco.

Developed to increase the number of hematologists from underrepresented backgrounds with academic and research appointments, the ASH-AMFDP Award provides four-year postdoctoral research grants to fellows aspiring to careers in academic medicine. Each recipient receives a total of $420,000 over the course of the program, including stipends and research grants, as well as the support of a National Advisory Committee mentor through the Robert Wood Johnson Foundation, complimentary ASH membership, and support for attendance at both the ASH and AMFDP annual meetings each year of the award.

“ASH is proud to support the careers of Drs. Weeks and Ramos, two rising stars in hematology,” said ASH President Martin Tallman, MD, of Memorial Sloan Kettering Cancer Center.

Lachelle Dawn Weeks, MD, PhD
Emilio Ramos, MD, PhD

Dr. Weeks, a fellow in hematology, has embarked on a research project that aims to identify novel clinical and genomic predictors of high-risk clonal hematopoiesis (CHIP) and to use CHIP as a biomarker to develop innovative screening and prevention strategies for individuals at risk of developing hematologic malignancies such as acute myeloid leukemia.

Dr. Ramos, a hematopathology fellow, will lead a collaborative project between two institutions to use unique technologies such as cell surface proteomics and a fully in vitro antibody discovery system to determine new targets for immunotherapy and drive development of new immunotherapies that can treat blast phase myeloproliferative neoplasms (MPN-BP), a rare form of acute leukemia associated with poor prognosis.

The ASH-AMFDP program is part of the ASH Minority Recruitment Initiative, which is dedicated to encouraging diversity in the field of hematology. Through various programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care communities.

Learn more about ASH’s commitment to diversity, equity, and inclusion in health care at hematology.org/DEI.


First 10 Sites Join ASH Research Collaborative SCD Clinical Trials Network

The ASH Research Collaborative (ASH RC) has announced the first 10 clinical research consortia to join the ASH RC Sickle Cell Disease Clinical Trials Network. The sites will be able to enroll children and adults living with sickle cell disease (SCD) within their patient populations in clinical trials as part of an unprecedented national effort to streamline operations and facilitate data sharing to expedite the development of new treatments.

The first 10 ASH RC Sickle Cell Disease Clinical Trials Network Sites are:

  • Central Carolinas Clinical Trials Collaboration
    Clinical Trials Unit: Duke University Medical Center (Adult & Pediatrics)
  • Chicagoland Regional Research in Sickle Cell Partnership (CRiSP)
    Clinical Trials Unit: Ann & Robert H. Lurie Children’s Hospital of Chicago
  • DMV Sickle Cell Disease Consortium (DMVSCDC)
    Clinical Trials Unit: Children’s National Health System
  • The Heartland/Southwest SCD Consortium
    Clinical Trials Unit: Washington University School of Medicine
  • New York Sickle Cell CTN Consortium
    Clinical Trials Unit: Montefiore Medical Center
  • North Texas Clinical Trials Consortium
    Clinical Trials Unit: UT Southwestern Medical Center
  • SCD Clinical and Research Consortium of Southeastern Wisconsin
    Clinical Trials Unit: Medical College of Wisconsin
  • Sickle Mid Atlantic Research Team (SMART)
    Clinical Trials Unit: The Johns Hopkins University School of Medicine
  • South Carolina Sickle Cell Disease Network
    Clinical Trials Unit: Prisma Health Children’s Hospital – Upstate
  • Western States Sickle Cell Disease Clinical Trials Network (WeSt SCD CTN)
    Clinical Trials Unit: UCSF Benioff Children’s Hospital of Oakland

Inclusiveness, commitment to rigorous standards, and improving the access of the SCD community to clinical trials are guiding principles of the SCD Clinical Trials Network. In addition to the 10 consortia that have already been activated, additional network sites are in the onboarding process. Additions to the SCD Network will continue to be announced on a rolling basis.

For more information about the network, visit ASHResearchCollaborative.org.